Sulfonylurea
This page covers all Sulfonylurea drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Sulfonylurea receptor 1, Kir6.2, ATP-sensitive potassium channel (KATP channel), Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel.
Targets
Sulfonylurea receptor 1, Kir6.2 · ATP-sensitive potassium channel (KATP channel) · Sulfonylurea receptor (SUR1) / ATP-sensitive potassium channel · SUR1/ Kir6.2 · ATP-sensitive potassium channels (K_ATP) · ATP-sensitive potassium channel (KATP channel) / Sulfonylurea receptor · SUR1 · Pancreatic beta-cell ATP-sensitive potassium channels
Marketed (9)
- Micronase · Sanofi · Metabolic
- Gliclazide (Comparison drug) · University of Glasgow · Diabetes
Gliclazide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. - Glimepiride (HOE490) · Sanofi · Diabetes
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. - Add Glimepiride · Samsung Medical Center · Diabetes
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. - Diabinese · Pfizer · Metabolic
- Comparator: Sulfonylurea · Merck Sharp & Dohme LLC · Diabetes
Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. - add-on sulphonylurea · Italian Society of Diabetology · Diabetes
Sulfonylureas stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes. - Aglicid · Metabolic
- Comparator: glimepiride · Merck Sharp & Dohme LLC · Diabetes
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane.
Phase 3 pipeline (7)
- Sulfonylurea (glimepiride) · GRADE Study Group · Diabetes
Glimepiride works by stimulating insulin release from the pancreatic beta cells. - Glimepiride Rescue Medication · Merck Sharp & Dohme LLC · Diabetes
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. - Placebo to glipizide · Merck Sharp & Dohme LLC · Diabetes
Glipizide stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels, thereby lowering blood glucose in type 2 diabetes. - Gliclazide MR-based glucose lowering · The George Institute · Diabetes
Gliclazide is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels. - Sulfonylureas (SU) · Janssen Research & Development, LLC · Diabetes
Sulfonylureas stimulate insulin release from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels. - Open-label Glimepiride · Merck Sharp & Dohme LLC · Diabetes
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptors on the cell membrane. - Glimepiride or gliclazide · Merck Sharp & Dohme LLC · Diabetes
Glimepiride and gliclazide stimulate insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
Phase 2 pipeline (2)
- Glipizide GITS · Pfizer · Diabetes
Sulfonylurea receptor agonist - Diabeton 60 MR · Servier Affaires Médicales · Diabetes
Diabeton 60 MR is a sustained-release formulation that provides prolonged glucose-lowering effects by inhibiting glucagon-like peptide-1 (GLP-1) degradation.